STALEY CAPITAL ADVISERS’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

STALEY CAPITAL ADVISERS’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.31M	Buy	18,065 +3,700	+26%	+$462K	0.1%	76
2025 Q4	$1.75M	Sell	14,365 -20	-0.1%	-$2.29K	0.07%	91
2025 Q3	$1.44M	Hold	14,385	–	–	0.06%	93
2025 Q2	$1.19M	Sell	14,385 -1,700	-11%	-$136K	0.05%	105
2025 Q1	$1.3M	Sell	16,085 -1,930	-11%	-$173K	0.06%	98
2024 Q4	$1.62M	Buy	18,015 +50	+0.3%	+$4.84K	0.07%	89
2024 Q3	$1.77M	Sell	17,965 -550	-3%	-$54K	0.08%	82
2024 Q2	$1.72M	Buy	18,515 +300	+2%	+$26.9K	0.08%	83
2024 Q1	$1.73M	Sell	18,215 -100	-0.5%	-$9.28K	0.08%	79
2023 Q4	$1.64M	Sell	18,315 -28,770	-61%	-$2.14M	0.08%	83
2023 Q3	$3.44M	Buy	47,085 +250	+0.5%	+$20K	0.19%	60
2023 Q2	$3.9M	Sell	46,835 -1,185	-2%	-$99.1K	0.21%	58
2023 Q1	$3.66M	Sell	48,020 -610	-1%	-$50.6K	0.2%	58
2022 Q4	$4.04M	Sell	48,630 -19,152	-28%	-$1.55M	0.24%	56
2022 Q3	$5.38M	Buy	67,782 +11,300	+20%	+$953K	0.34%	50
2022 Q2	$4.2M	Buy	56,482 +15,640	+38%	+$1.17M	0.25%	55
2022 Q1	$3.67M	Buy	+40,842	New	+$3.77M	0.19%	63

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

STALEY CAPITAL ADVISERS's XBI Position: Q1 2026 in Review

STALEY CAPITAL ADVISERS increased its State Street SPDR S&P Biotech ETF (XBI) stake by 26% in Q1 2026, buying an estimated $462K and bringing the position to 18,065 shares worth $2.31M. The position accounts for 0.1% of the portfolio, ranked #76.

STALEY CAPITAL ADVISERS first reported a position in XBI in Q1 2022 and has held it in 17 quarters since. The position peaked at $5.38M in Q3 2022. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

STALEY CAPITAL ADVISERS held 18,065 shares of State Street SPDR S&P Biotech ETF worth $2.31M as of Q1 2026.
STALEY CAPITAL ADVISERS bought 3,700 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $462K.
State Street SPDR S&P Biotech ETF made up 0.1% of STALEY CAPITAL ADVISERS's portfolio in Q1 2026, its #76 holding.
STALEY CAPITAL ADVISERS first reported a position in State Street SPDR S&P Biotech ETF in Q1 2022 and has held it in 17 quarters since.
STALEY CAPITAL ADVISERS's State Street SPDR S&P Biotech ETF position peaked at $5.38M in Q3 2022.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on STALEY CAPITAL ADVISERS's 13F filing for Q1 2026, filed 29 Apr 2026.